

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
February 24, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934

February 24, 2005  
Date of Report (Date of earliest event reported)

-----  
ANTIGENICS INC  
(Exact name of registrant as specified in its charter)

-----  
DELAWARE  
(State or other jurisdiction  
of incorporation)

000-29089  
(Commission  
File Number)

06-1562417  
(IRS Employer  
Identification No.)

630 Fifth Avenue, Suite 2100  
New York, NY 10111  
(Address of principal executive offices)

10111  
(Zip Code)

212-994-8200  
(Registrant's telephone number, including area code)

-----  
Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange  
Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange  
Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On February 24, 2005, Antigenics Inc. announced its financial  
results for the quarter ended December 31, 2004. The full text  
of the press release issued in connection with the  
announcement is being furnished as Exhibit 99.1 to this  
current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

(c) Exhibits:

99.1 Press Release dated February 24, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: February 24, 2005

By: /s/ Garo H. Armen

-----

Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

EXHIBIT INDEX

The following designated exhibits are filed herewith:

Exhibits:

99.1 Press Release dated February 24, 2005